Literature DB >> 23688539

Assessing the effect of providing a pharmacist with patient diagnosis on electronic prescription orders: a pilot study.

Terri L Warholak1, Michael T Rupp, Sandra Leal, Guntur Kurniawan, Nisha Patel.   

Abstract

BACKGROUND: As a result of the US Omnibus Reconciliation Act of 1990 (OBRA '90), pharmacists have the obligation to ensure that prescription orders are appropriate and are not likely to cause adverse events. However, patient diagnosis information is not a requirement for a legal prescription order in any state in the US.
OBJECTIVE: To compare a pharmacist's interventions before and after patient diagnosis is added by prescribers to their electronic prescription orders.
METHODS: This prospective, pre-post study was conducted during two consecutive 4-week periods in a community health center pharmacy. During the first data collection period, the clinical pharmacist prospectively evaluated e-prescriptions using a standard DUR protocol. All problematic prescriptions were documented using a medication intervention form. During the second data collection period, providers included the patient's diagnosis on each e-prescription and the same clinical pharmacist again evaluated prescribed therapy and documented interventions.
RESULTS: Pharmacist intervention rates on e-prescription orders were significantly lower following addition of the patient diagnosis information to the e-prescription order (3.9% pre- vs. 1.0% post-, P < 0.001).
CONCLUSIONS: While preliminary, the results of this pilot suggest that the addition of patient diagnosis to the e-prescription order can reduce confusion and uncertainty on the part of a DUR pharmacist, thereby decreasing the overall number of interventions and the subsequent number of contacts with prescribers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Information exchange; Intervention; Pharmacist; e-prescription

Mesh:

Year:  2013        PMID: 23688539     DOI: 10.1016/j.sapharm.2013.04.010

Source DB:  PubMed          Journal:  Res Social Adm Pharm        ISSN: 1551-7411


  7 in total

1.  Pharmacists' perspectives on the value of reason for use information.

Authors:  Colin Whaley; Ashley Bancsi; Catherine Burns; Kelly Grindrod
Journal:  Can Pharm J (Ott)       Date:  2020-08-18

2.  Medication management surrounding transitions of care: A qualitative assessment of community pharmacists' preferences (MEMO TOC).

Authors:  Miranda Hambrook; Shaylee Peterson; Sean Gorman; Greg Becotte; Andrea Burrows
Journal:  Can Pharm J (Ott)       Date:  2020-08-27

3.  What do Australian consumers, pharmacists and prescribers think about documenting indications on prescriptions and dispensed medicines labels?: A qualitative study.

Authors:  Mona Garada; Andrew J McLachlan; Gordon D Schiff; Elin C Lehnbom
Journal:  BMC Health Serv Res       Date:  2017-11-15       Impact factor: 2.655

4.  Prescribers' perspectives on including reason for use information on prescriptions and medication labels: a qualitative thematic analysis.

Authors:  Colin Whaley; Ashley Bancsi; Joanne Man-Wai Ho; Catherine M Burns; Kelly Grindrod
Journal:  BMC Health Serv Res       Date:  2021-01-26       Impact factor: 2.655

Review 5.  Including the Reason for Use on Prescriptions Sent to Pharmacists: Scoping Review.

Authors:  Kathryn Mercer; Caitlin Carter; Catherine Burns; Ryan Tennant; Lisa Guirguis; Kelly Grindrod
Journal:  JMIR Hum Factors       Date:  2021-11-25

6.  Incorporating 'reason for use' into the prescribing process of medication: a survey on the opinion of patients in Flanders, Belgium.

Authors:  Marijke Peeters; Elias Iturrospe; Dominique Jans; Alexander L N van Nuijs; Hans De Loof
Journal:  BMC Health Serv Res       Date:  2022-09-30       Impact factor: 2.908

7.  Systematic review and meta-analysis of community pharmacy error rates in the USA: 1993-2015.

Authors:  Patrick J Campbell; Mira Patel; Jennifer R Martin; Ana L Hincapie; David Rhys Axon; Terri L Warholak; Marion Slack
Journal:  BMJ Open Qual       Date:  2018-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.